Education
About Us
Working with TipRanks
Follow Us
Neola Medical AB (SE:NEOLA)
:NEOLA
Top Page
Neola Medical AB
(NEOLA)
Select Model
Select Model
Rating:45Neutral
Price Target:
kr1.00
▼(-7.41% Downside)
The score is held back primarily by very weak operating performance (zero revenue, ongoing losses) and continued cash burn. A debt-free balance sheet provides some support, but technicals remain bearish with the stock below key moving averages, and valuation is hard to justify from a negative P/E with no dividend data.
Neola Medical AB (NEOLA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr82.63M
Dividend YieldN/A
Average Volume (3M)12.79K
Price to Earnings (P/E)―
Beta (1Y)0.01
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees7
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.04
Shares Outstanding77,950,230
10 Day Avg. Volume10,323
30 Day Avg. Volume12,794
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)2.05
Price to Sales (P/S)0.00
P/FCF Ratio-13.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Neola Medical AB Business Overview & Revenue Model
Company DescriptionNeola Medical AB (publ) develops medical equipment for continuous monitoring of the lungs of premature babies. It offers neonatal intensive care with NEOLA, a medical device that offer continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume changes and oxygen gas concentration. NEOLA provides intensive care and healthier lives for preterm born infants. The company was formerly known as GPX Medical AB and changed its name to Neola Medical AB (publ) in June 2022. Neola Medical AB (publ) was incorporated in 2016 and is headquartered in Lund, Sweden.
How the Company Makes Money
Neola Medical AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 625.00K | 31.00K |
| Gross Profit | 5.85M | -1.53M | -1.43M | -571.00K | -7.36M | -7.85M |
| EBITDA | -7.58M | -8.54M | -7.58M | -9.82M | -6.64M | -6.71M |
| Net Income | -8.35M | -10.06M | -9.01M | -10.35M | -6.65M | -6.72M |
Balance Sheet | ||||||
| Total Assets | 82.61M | 73.61M | 86.02M | 75.33M | 43.83M | 25.97M |
| Cash, Cash Equivalents and Short-Term Investments | 22.12M | 19.55M | 21.58M | 40.09M | 22.94M | 16.64M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 4.15M | 4.65M | 6.99M | 7.84M | 3.19M | 2.42M |
| Stockholders Equity | 78.46M | 68.96M | 79.03M | 67.48M | 40.63M | 23.55M |
Cash Flow | ||||||
| Free Cash Flow | -2.54M | -10.84M | -18.85M | -20.05M | -17.45M | -8.25M |
| Operating Cash Flow | -8.54M | -10.84M | -6.54M | -8.50M | -6.93M | -6.08M |
| Investing Cash Flow | -6.52M | -11.18M | -12.30M | -11.56M | -10.52M | -2.17M |
| Financing Cash Flow | -92.00K | 20.00M | 336.00K | 37.20M | 23.74M | 19.54M |
Neola Medical AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:NEOLA
Neola Medical AB
1.08
-1.47
-57.68%
DE:5J3
SciBase Holding AB
0.04
0.02
133.33%
DE:LS60
Clinical Laserthermia Systems AB Class B
0.70
0.46
189.67%
DE:LUR
Luxbright AB
0.04
-0.03
-39.68%
SE:NOSA
Nosa Plugs AB
0.58
-0.37
-38.95%
SE:ARCOMA
Arcoma AB
7.62
-3.28
-30.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.